Vaxxinity, Inc. (VAXX) |
|
2.34 -0.03 (-1.27%)
|
03-22 11:02 |
|
Open: |
2.39 |
Pre. Close: |
2.37 |
|
High:
|
2.39 |
Low:
|
2.24 |
|
Volume:
|
23,744 |
Market Cap:
|
295(M) |
|
|
|
Technical analysis |
as of: 2023-03-22 10:50:07 AM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 3.04  One year: 3.56 |
| Support: |
Support1: 2.15 Support2: 1.87 |
| Resistance: |
Resistance1: 2.6 Resistance2: 3.04 |
| Pivot: |
2.2 |
| Moving Average: |
MA(5): 2.19  MA(20): 2.23
MA(100): 2.16 MA(250): 2.54 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 51.3 %D(3): 40.1 |
| RSI: |
RSI(14): 49.8 |
| 52-week: |
High: 8.35 Low: 1.24 |
| Average Vol(K): |
3-Month: 350 (K) 10-Days: 146 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ VAXX ] has closed below upper band by 27.1%. Bollinger Bands are 49.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 13 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.41 - 2.43 |
2.43 - 2.44 |
|
Low:
|
2 - 2.02 |
2.02 - 2.03 |
|
Close:
|
2.34 - 2.37 |
2.37 - 2.39 |
|
Company Description |
|
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas. |
Headline News |
Wed, 01 Mar 2023
ICR Hosts Vaxxinity CEO Mei Mei Hu on the Welcome to the Arena ... - Business Wire
Thu, 09 Feb 2023
Vaxxinity moves HQ, jobs to Florida's Space Coast from Texas - The Business Journals
Mon, 23 Jan 2023
Vaxxinity up 23% as 2023 surge continues; up 158% year to date ... - Seeking Alpha
Thu, 19 Jan 2023
Why Shares of Vaxxinity Jumped This Week - Nasdaq
Thu, 05 Jan 2023
Vaxxinity to Present at the 2023 J.P. Morgan Healthcare Conference - Yahoo Finance
Thu, 10 Nov 2022
Vaxxinity Reports Third Quarter 2022 Financial Results and Provides Corporate Update - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
-26 (M) |
| Shares Float |
0 (M) |
|
% Held by Insiders
|
1.1218e+008 (%) |
|
% Held by Institutions
|
3.265e+007 (%) |
|
Shares Short
|
0 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.87e+006 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
-1.39 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
10 |
|
Return on Assets (ttm)
|
290 |
|
Return on Equity (ttm)
|
600 |
|
Qtrly Rev. Growth
|
-118.1 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-0.79 |
|
Qtrly Earnings Growth
|
-1.0159e+008 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0.1 |
|
Price to Book value
|
-1.7 |
|
Price to Sales
|
3894.87 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
932660 |
|
Forward Dividend
|
957060 |
|
Dividend Yield
|
39857300% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
